Saaim Khan supports Sterling Atlantic’s healthcare investments, including arranging strategic relationships across clinical, academic, and industry ecosystems. With a background in translational genomics and early-stage investing, Saaim brings a unique ability to bridge scientific depth with commercial insight.

He currently studies medicine at Harvard Medical School and conducts research at Boston Children’s Hospital on the genetic basis of hearing loss, with a focus on improving diagnostic tools using Oxford Nanopore sequencing. His previous experience includes sourcing and evaluating healthtech startups at Remus Capital and advancing accessibility-focused technologies like TranscribeGlass. Saaim also contributes to patient advocacy through roles with the Hearing Loss Association of America and the Museum of Science Boston.